中国新药杂志

新型冠状病毒中和抗体的研发进展

PDF下载

乐鑫 ¹^,² , 潘勇兵 ¹^,² , 杨晓明 ²^,³

中国新药杂志 | 生物医药前沿 2021,30(19): 1752-1758

收起

中国新药杂志 |生物医药前沿 2021 , 30 (19) : 1752 -1758

新型冠状病毒中和抗体的研发进展

全屏

乐鑫¹^,², 潘勇兵¹^,², 杨晓明²^,³

作者信息

¹武汉生物制品研究所，武汉　430207

²国家联合疫苗工程技术研究中心，武汉　430207

³中国生物技术股份有限公司，北京　100029

通讯作者:

杨晓明，男，博士生导师，研究方向：生物制品的开发与管理。E-mail：yangxiaoming@sinopharm.com。

作者简介:

乐鑫，男，博士，研究方向：治疗性单克隆抗体的开发。E-mail：bioyuexin@126.com。

Research and development progress of SARS-CoV-2 neutralizing antibody

Xin YUE¹^,², Yong-bing PAN¹^,², Xiao-ming YANG²^,³

Affiliations

¹Wuhan Institute of Biological Products, Wuhan 430207, China

²National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China

³China National Biotec Group Company Limited, Beijing 100029, China

出版时间: 2021-10-15

文章导航

摘要

收起

新型冠状病毒（SARS-CoV-2）已在全球范围广泛传播，对经济发展和人类生活造成了重大影响，开发安全有效的药物成为当务之急。中和抗体在部分病毒感染性疾病的临床应用中取得良好效果，既可用于SARS-CoV-2感染的短期预防，也可用于新型冠状病毒肺炎的治疗，具有重要的应用价值。目前国内外SARS-CoV-2中和抗体的研发进展迅速，多个抗体药物进入临床试验或投入紧急使用。本文主要从SARS-CoV-2中和抗体的靶点、筛选技术、药物研发进展及需要关注的问题等方面进行了总结。

关键词

新型冠状病毒 / 中和抗体 / 临床试验 / 免疫逃逸

Abstract

收起

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has widely spread around the world, exerting great impacts on economic growth and human life. It is the highest priority to develop safe and effective drugs. Neutralizing antibodies have achieved good results in previous clinical applications of some viral infectious diseases. They can be used not only for the short-term prevention of SARS-COV-2 infection, but also for the treatment of corona virus disease 2019 (COVID-19), showing important application value. At present, the research and development of SARS-CoV-2 neutralizing antibody has made its rapid progress in China and abroad. Many antibody drugs have entered clinical trials and been put into emergency use. This article mainly summarizes targets of SARS-CoV-2 neutralizing antibody, screening technologies, drug development progresses and problems to be concerned.

Key words

SARS-CoV-2 / neutralizing antibody / clinical trial / immune escape

引用本文

乐鑫, 潘勇兵, 杨晓明. 新型冠状病毒中和抗体的研发进展. 中国新药杂志, 2021 , 30 (19) : 1752 -1758 .

Xin YUE, Yong-bing PAN, Xiao-ming YANG. Research and development progress of SARS-CoV-2 neutralizing antibody[J]. Chinese Journal of New Drugs, 2021 , 30 (19) : 1752 -1758 .

基金

收起

国家科技部重点专项资助项目(2020YFC0841800)
2019-nCoV感染恢复期患者特异血浆和特异免疫球蛋白制备

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

[1]

ZHOU P, YANG XL, WANG XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature, 2020, 579(7798): 270-273.

[2]

DUAN K, LIU B, LI C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients[J]. Proc Natl Acad Sci, 2020, 117(17): 9490-9496.

[3]

WANG Y, ZHANG D, DU G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial[J]. Lancet, 2020, 395(10236): 1569-1578.

[4]

GAUDINSKI MR, COATES EE, NOVIK L, et al. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study[J]. Lancet, 2019, 393(10174): 889-898.

[5]

DOMACHOWSKE JB, KHAN AA, ESSER MT, et al. Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants[J]. Pediatr Infect Dis J, 2018, 37(9): 886-892.

[6]

KE Z, OTON J, QU K, et al. Structures and distributions of SARS-CoV-2 spike proteins on intact virions[J]. Nature, 2020, 588(7838): 498-502.

[7]

TORTORICI MA, VEESLER D. Structural insights into coronavirus entry[J]. Adv Virus Res, 2019, 105: 93-116.

[8]

WALL AC, PARK YJ, TORTORICI MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein[J]. Cell, 2020, 181(2): 281-292.

[9]

WRAPP D, WANG N, CORBETT KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation[J]. Science, 2020, 367(6483): 1260-1263.

[10]

DEJNIRATTISAI W, ZHOU D, GINN HM, et al. The antigenic anatomy of SARS-CoV-2 receptor binding domain[J]. Cell, 2021, 184(8): 2183-2200.

[11]

HARVEY WT, CARABELLI AM, JACKSON B, et al. SARS-CoV-2 variants, spike mutations and immune escape[J]. Nat Rev Microbiol, 2021, 19(7): 409-424.

[12]

WHO. Tracking SARS-CoV-2 variants[EB/OL]. [2021-09-22]. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.

[13]

VOLZ E, MISHRA S, CHAND M, et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England[J]. Nature, 2021, 593(7858): 266-269.

[14]

TEGALLY H, WILKINSON E, GIOVANETTI M, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa[J]. MedRxiv, 2020, doi: 10.1101/2020.12.21.20248640.

[15]

SABINO EC, BUSS LF, CARVALHO MPS, et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence[J]. Lancet, 2021, 397(10273): 452-455.

[16]

VAIDYANATHAN G. Coronavirus variants are spreading in India-what scientists know so far[J]. Nature, 2021, 593(7859): 321-322.

[17]

JONES BE, BROWN-AUGSBURGER PL, CORBETT KS, et al. LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection[J]. BioRxiv, 2020, doi: 10.1101/2020.09.30.318972.

[18]

SHI R, SHAN C, DUAN X, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2[J]. Nature, 2020, 584(7819): 120-124.

[19]

PAN Y, DU J, LIU J, et al. Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries[J]. Cell Discov, 2021, 7(1): 57.

[20]

SUN D, SANG Z, KIM YJ, et al. Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes[J]. Nat Commun, 2021, 12(1): 4676.

[21]

HANSEN J, BAUM A, PASCAL KE, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail[J]. Science, 2020, 369(6506): 1010-1014.

[22]

KIM SII, NOH J, KIM S, et al. Stereotypic neutralizing VH antibodies against SARS-CoV-2 spike protein receptor binding domain in COVID-19 patients and healthy individuals[J]. Sci Transl Med, 2021, 13(578): eabd6990.

[23]

PINTO D, PARK YJ, BELTRAMELLO M, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody[J]. Nature, 2020, 583(7815): 290-295.

[24]

BARNES CO, JETTE CA, ABERNATHY ME, et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies[J]. Nature, 2020, 588(7839): 682-687.

[25]

WEINREICH DM, SIVAPALASINGAM S, NORTON T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19[J]. N Engl J Med, 2021, 384(3): 238-251.

[26]

GOTTLIEB RL, NIRULA A, CHEN P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial[J]. JAMA, 2021, 325(7): 632-644.

[27]

CAO Y, SU B, GUO X, et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells[J]. Cell, 2020, 182(1): 73-84.

[28]

JU B, ZHANG Q, GE J, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection[J]. Nature, 2020, 584(7819): 115-119.

[29]

ClinicalTrials. gov. ClinicalTrials.gov is a resource provided by the U. S. National Library of Medicine[EB/OL]. [2021-09-06]. https://clinicaltrials.gov/ct2/home.

[30]

SURYADEVARA N, SHRIHARI S, GILCHUK P, et al. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein[J]. Cell, 2021, 184(9): 2316-2331.

[31]

KANG S, YANG M, HE S, et al. A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation[J]. Nat Commun, 2021, 12(1): 2697.

[32]

GASPARO RD, PEDOTTI M, SIMONELLI L, et al. Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice[J]. Nature, 2021, 593(7859): 424-428.

[33]

KU Z, XIE X, HINTON PR, et al. Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants[J]. Nature, 2021, 595(7869): 718-723.

[34]

HUANG KY, LIN MS, KUO TC, et al. Humanized COVID-19 decoy antibody effectively blocks viral entry and prevents SARS-CoV-2 infection[J]. EMBO Mol Med, 2021, 13(1): e12828.

[35]

HO D, WANG P, LIU L, et al. Increased resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization[J]. Res Sq, 2021, PMID: 33532763.

[36]

PLANAS D, VEYER D, BAIDALIUK A, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization[J]. Nature, 2021, 596(7871): 276-280.

[37]

BAUM A, FULTON BO, WLOGA E, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies[J]. Science, 2020, 369(6506): 1014-1018.

[38]

CHAQROUN A, HARTARD C, SCHVOERER E. Anti-SARS-CoV-2 vaccines and monoclonal antibodies facing viral variants[J]. Viruses, 2021, 13(6): 1171.

[39]

KIM HW, CANCHOLA JG, BRANDT CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine[J]. Am J Epidemiol, 1969, 89(4): 422-434.

[40]

TOLTZIS P. 50 Years ago in the journal of pediatrics: atypical exanthem after exposure to natural measles: eleven cases in children previously inoculated with killed vaccine[J]. J Pediatr, 2018, 193: 84.

[41]

DEJNIRATTISAI W, JUMNAINSONG A, ONSIRISAKUL N, et al. Cross-reacting antibodies enhance dengue virus infection in humans[J]. Science, 2010, 328(5979): 745-748.

[42]

YIP MS, LEUNG HL, LI PH, et al. Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS[J]. Hong Kong Med J, 2016, 22(3 Suppl 4): S25-S31.

[43]

WAN Y, SHANG J, SUN S, et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry[J]. J Virol, 2020, 94(5): e02015-e02019.

[44]

LI D, EDWARDS RJ, MANNE K, et al. In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies[J]. Cell, 2021, 184(16): 4203-4219.

[45]

ARVIN AM, FINK K, SCHMID MA, et al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2[J]. Nature, 2020, 584(7821): 353-363.

[46]

ULLAH I, PREVOST J, LADINSKY MS, et al. Live imaging of SARS-CoV-2 infection in mice reveals neutralizing antibodies require Fc function for optimal efficacy[J]. BioRxiv, 2021, doi: 10.1101/2021.03.22.436337.

[47]

Regeneron Pharmaceuticals Inc. Regen-Cov^TM (Casirivimab and Imdevimab) phase 3 recovery trial meets primary outcome, improving survival in hospitalized COVID-19 patients lacking an immune response to SARS-COV-2[EB/OL]. [2021-06-16]. https://investor.regeneron.com/news-releases/news-release-details/regen-covtm-casirivimab-and-imdevimab-phase-3-recovery-trial.

[48]

HUANG C, WANG Y, LI X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(10223): 497-506.

[49]

STARR TN, CZUDNOCHOWSKI N, LIU Z, et al. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape[J]. Nature, 2021, PMID: 34261126.

2021年第30卷第19期

PDF下载

引用本文

BibTeX

文章信息

首发时间：2026-10-30
出版时间：2021-10-15

补充材料

相关文章

文章信息

作者

出版历史

录用日期：2021-09-06

基金

国家科技部重点专项资助项目(2020YFC0841800)

2019-nCoV感染恢复期患者特异血浆和特异免疫球蛋白制备

作者信息

¹武汉生物制品研究所，武汉　430207

²国家联合疫苗工程技术研究中心，武汉　430207

³中国生物技术股份有限公司，北京　100029

通讯作者:

杨晓明，男，博士生导师，研究方向：生物制品的开发与管理。E-mail：yangxiaoming@sinopharm.com。

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zgxyzz/CN/1322906855877509228

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT